Characteristics | Mean (min.-max.) | SD |
---|---|---|
Age at diagnosis, years | 55.1 (38–69) | 7.89 |
Education, years | 15.8 (8–24) | 3.47 |
Postmenopausal, no (%) | 38 (68Â %) | Â |
Systolic BP, mmHg | 132 (87–184) | 22.9 |
Diastolic BP, mmHg | 77.4 (58–108) | 11.9 |
Height, cm | 167 (155–181) | 5.97 |
Weight, kg | 70.5 (49–97) | 11.6 |
BMI, kg/m2 | 25.1 (20.0–33.2) | 3.48 |
Statin use, no (%) | 3 (5Â %) | Â |
Serum lipoproteins | ||
 Cholesterol, mmol/L | 5.74 (4.00–8.00) | 1.00 |
 HDL-cholesterol, mmol/L | 1.78 (1.00–3.00) | 0.49 |
 LDL-cholesterol, mmol/L | 3.45 (1.31–5.49) | 0.98 |
 Triglycerides, mmol/L | 1.18 (0–3) | 0.59 |
 Apolipoprotein-A, mmol/L | 1.67 (1–3) | 0.29 |
 Apolipoprotein-B, mmol/L | 1.04 (0–2) | 0.27 |
Tumor characteristics | ||
 Tumor diameter, mm | 16.4 (4–40) | 8.52 |
 Grade 1–3 | 1.96 (1–3) | 0.71 |
 Ki-67 hotspot, % | 26.5 (1–81) | 21.8 |
 Nodal metastasis, no | 0,75 (0–11) | 2.13 |
 ER positive, no (%) | 52 (93 %) |  |
 ER percent | 88,1 (0–100) | 26.9 |
 PgR positive, no (%) | 46 (82 %) |  |
 PgR percent | 64,2 (0–100) | 36.8 |
 Hormone receptor negative, no (%) | 4 (7 %) |  |
 HER2 positive, no (%) | 3 (5 %) |  |